Sanofi (SNY)

42.02
0.37 0.89
NASDAQ : Health Technology
Prev Close 41.65
Open 41.82
Day Low/High 41.81 / 42.33
52 Wk Low/High 40.00 / 45.62
Volume 973.04K
Avg Volume 1.49M
Exchange NASDAQ
Shares Outstanding 2.49B
Market Cap 104.08B
EPS 2.00
P/E Ratio 22.39
Div & Yield 1.16 (2.77%)

Latest News

Alphabet Shares Soar After Excellent Earnings Results

Alphabet Shares Soar After Excellent Earnings Results

A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed near session highs Monday.

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

The charges were related to an interest-rate problem.

Nationalized 5G and Everything Else You Need to Know Before You Trade Monday

Nationalized 5G and Everything Else You Need to Know Before You Trade Monday

As the Trump administration reportedly considers government controlled 5G, investors prepare for a hectic week of earnings.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?

Government Shutdown and Everything Else You Need to Know Monday Morning

Government Shutdown and Everything Else You Need to Know Monday Morning

So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.

Winners and Losers in a Temporary French Tax Revolution

Winners and Losers in a Temporary French Tax Revolution

Some French companies will get a temporary windfall, but others will need to pay more tax.

These 16 Stocks Look Ready to Reverse

These 16 Stocks Look Ready to Reverse

Tesla and General Motors are among this week's names showing reversal patterns.

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Investors keep an eye on another busy slate of earnings.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Shark Tank's Robert Herjavec on why the Equifax hack is different from others cyber attacks.

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Mailbag: Buy Dip in T2 Biosystems?

Plus, what's going on with Lexicon Pharmaceuticals?

Sanofi Has Good Potential Upside

Sanofi Has Good Potential Upside

I would buy strength above $50 and $51 in Sanofi.

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Ed Kaye said he's stepping down.

HSBC Security Downgrades Sanofi

HSBC Security Downgrades Sanofi

The stock was trading slightly lower this afternoon.

Second-Quarter Picks and Pans

Second-Quarter Picks and Pans

Las Vegas Sands and Flexion are in, and the autos are out.

Sanofi to Pay for Drug Overcharges

Sanofi to Pay for Drug Overcharges

Sanofi SA agreed to a U.S. Department of Justice a $19.8 million fine for overcharging the U.S. Department of Veteran Affairs.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.